Join Growin Stock Community!

Akebia therapeutics, inc.AKBA.US Overview

US StockHealthcare
(No presentation for AKBA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AKBA AI Insights

AKBA Overall Performance

AKBA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AKBA Recent Performance

-3.44%

Akebia therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AKBA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AKBA Key Information

AKBA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AKBA Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Price of AKBA

AKBA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AKBA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.02
PE Ratio (TTM)
-
Forward PE
3.83
PS Ratio (TTM)
1.47
PB Ratio
8.42
Price-to-FCF
4.94
METRIC
VALUE
vs. INDUSTRY
Gross Margin
83.29%
Net Margin
-2.26%
Revenue Growth (YoY)
47.46%
Profit Growth (YoY)
102.81%
3-Year Revenue Growth
1.45%
3-Year Profit Growth
-8.20%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.02
PE Ratio (TTM)
-
Forward PE
3.83
PS Ratio (TTM)
1.47
PB Ratio
8.42
Price-to-FCF
4.94
Gross Margin
83.29%
Net Margin
-2.26%
Revenue Growth (YoY)
47.46%
Profit Growth (YoY)
102.81%
3-Year Revenue Growth
1.45%
3-Year Profit Growth
-8.20%

  • When is AKBA's latest earnings report released?

    The most recent financial report for Akebia therapeutics, inc. (AKBA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AKBA's short-term business performance and financial health. For the latest updates on AKBA's earnings releases, visit this page regularly.

  • What is the operating profit of AKBA?

    According to the latest financial report, Akebia therapeutics, inc. (AKBA) reported an Operating Profit of -7.65M with an Operating Margin of -13.28% this period, representing a growth of 42.61% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AKBA's revenue growth?

    In the latest financial report, Akebia therapeutics, inc. (AKBA) announced revenue of 57.62M, with a Year-Over-Year growth rate of 23.93%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does AKBA have?

    At the end of the period, Akebia therapeutics, inc. (AKBA) held Total Cash and Cash Equivalents of 184.84M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AKBA go with three margins increasing?

    In the latest report, Akebia therapeutics, inc. (AKBA) did not achieve the “three margins increasing” benchmark, with a gross margin of 78.2%%, operating margin of -13.28%%, and net margin of -21.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AKBA's profit trajectory and future growth potential.

  • Is AKBA's EPS continuing to grow?

    According to the past four quarterly reports, Akebia therapeutics, inc. (AKBA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AKBA?

    Akebia therapeutics, inc. (AKBA)'s Free Cash Flow (FCF) for the period is 31.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 797.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.